Arbutus Biopharma Corp
ABUS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABUS
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B (cHBV) and leveraging its lipid nanoparticle (LNP) technology, with ongoing patent litigation against Pfizer/BioNTech and Moderna.
Key risk: Limited cash runway
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.00B
Cash Runway
71.5 moLead Asset
AB-101 (Phase 1)Next Catalyst
Phase3_Topline · Aug 15, 2030Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 2 catalysts for Arbutus Biopharma Corp.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B (cHBV) and leveraging its lipid nanoparticle (LNP) technology, with ongoing patent litigation against Pfizer/BioNTech and Moderna.
- Arbutus is developing imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, for chronic hepatitis B [sec_mda · as of 2025-03-27].
- As of June 30, 2026, the company reported cash & equivalents of $19.2M, total revenue of $1.0M, and a net loss of -$5.1M [sec].
- Cash used in operating activities for the six months ended June 30, 2026 was $14.1M, down from $29.1M in the prior-year period, due to workforce reductions and organizational streamlining [sec_mda · as of 2026-08-12].
- Arbutus holds an ownership stake in Genevant Sciences and is entitled to 20% of the Noncontingent Settlement Payment from the Moderna Settlement Agreement, with a potential return of capital to shareholders in Q3 2026 [sec_mda · as of 2026-03-23].
- The company has ongoing patent litigation against Pfizer/BioNTech and a §1498 appeal related to Moderna, which may affect future funding needs [sec_mda · as of 2026-08-12].
What works
- Arbutus has reduced its net cash burn significantly, with operating cash use declining from $29.1M to $14.1M for the first half of 2026, reflecting disciplined cost management [sec_mda · as of 2026-08-12].
- The company is entitled to 20% of the Noncontingent Settlement Payment from the Moderna Settlement Agreement, providing a potential near-term capital inflow [sec_mda · as of 2026-03-23].
- Arbutus owns approximately 16% of Genevant Sciences, giving it a stake in a company with LNP technology that may generate future value [sec_mda · as of 2026-03-23].
- The company has established a Scientific Advisory Board of global leaders in cHBV to guide its pipeline strategy [sec_mda · as of 2026-03-23].
What to weigh
- Arbutus has a limited cash position of $19.2M as of June 30, 2026, and expects to require substantial additional funds to continue active development of its pipeline [sec_mda · as of 2026-08-12].
- The company has an accumulated deficit and ongoing net losses, with a net loss of -$5.1M for the latest quarter [sec].
- Arbutus faces contingent payment obligations of up to $102.5M upon achievement of commercial milestones related to the Enantigen acquisition, which could strain future finances [sec_mda · as of 2026-03-23].
- The company's pipeline is still in clinical stages, with no approved products, and development timelines are subject to regulatory and clinical risks [sec_mda · as of 2026-03-23].
From the filings
Quoted directly from source documents.
Arbutus is developing imdusiran and AB-101 for chronic hepatitis B.
“We are currently developing imdusiran (AB-729), our proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).”
SEC MD&A · March 27, 2025
Cash used in operating activities decreased significantly in the first half of 2026.
“For the six months ended June 30, 2026, $14.1 million of cash was used in operating activities compared to $29.1 million used in operating activities for the six months ended June 30, 2025, a decrease of $15.0 million.”
SEC MD&A · August 12, 2026
Arbutus is entitled to 20% of the Noncontingent Settlement Payment from Moderna.
“Under our license with Genevant, we are entitled to receive, after deduction of litigation costs, 20% of the Noncontingent Settlement Payment.”
SEC MD&A · March 23, 2026
The company has contingent payment obligations of up to $102.5 million.
“we have obligations to make potential future payments of up to $102.5 million upon the achievement of certain commercial milestones.”
SEC MD&A · March 23, 2026
Catalyst timeline
- 2030-08-15 · Phase3_Topline · eribulin — Phase 3 Topline — Topline results from a Phase 3 trial of eribulin with gemcitabine versus standard of care; this is a distant catalyst with uncertain relevance to Arbutus's core pipeline.
- 2032-08-15 · Patent_Expiry · VEMLIDY — Patent/exclusivity expiry for VEMLIDY, which may affect competitive dynamics in the HBV space.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $19.2M as of June 30, 2026 may not be sufficient to fund all planned operations without additional financing [sec].
- Dependence on litigation outcomes — Future funding and potential capital return depend on outcomes of patent cases against Pfizer/BioNTech and Moderna [sec_mda · as of 2026-08-12].
- Contingent milestone payments — Up to $102.5M in potential payments tied to commercial milestones could strain finances if triggered [sec_mda · as of 2026-03-23].
- Clinical and regulatory delays — Pipeline products are in clinical stages and subject to delays, regulatory decisions, and competition [sec_mda · as of 2026-03-23].
What to watch
- Outcome of the Moderna §1498 appeal and any return of capital to shareholders, expected in Q3 2026 [sec_mda · as of 2026-03-23].
- Progress of imdusiran and AB-101 clinical trials for chronic hepatitis B [sec_mda · as of 2025-03-27].
- Cash burn rate and any additional financing or partnership deals to extend runway [sec_mda · as of 2026-08-12].
- Developments in patent litigation against Pfizer/BioNTech and the U.S. government [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Arbutus Biopharma Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Arbutus Biopharma Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
71.5 months
D/E 0.06 · 0% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~1446d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
168
Total value held
$571.7M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 25,891,480 | $116.5M |
| two seas capital lp | 18,557,543 | $83.5M |
| vanguard capital management llc | 13,377,822 | $60.2M |
| blackrock, inc. | 12,966,946 | $58.4M |
| state street corp | 6,342,510 | $28.5M |
| barclays plc | 4,316,095 | $19.4M |
| woodline partners lp | 4,020,344 | $18.1M |
| geode capital management, llc | 3,771,806 | $17.0M |
| adar1 capital management, llc | 3,133,175 | $14.1M |
| adage capital partners gp, l.l.c. | 2,664,941 | $12.0M |
Showing top 10 of 168 institutional holders of Arbutus Biopharma Corp. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.4%
- Days to cover
- 8.8
- Shares short
- 17,743,389
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABUS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Arbutus Biopharma Corp?
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B (cHBV) and leveraging its lipid nanoparticle (LNP) technology, with ongoing patent litigation against Pfizer/BioNTech and Moderna.
What is Arbutus Biopharma Corp's lead drug candidate?
Arbutus Biopharma Corp's most advanced tracked candidate is AB-101 (Phase 1) for Chronic Hepatitis b.
What is Arbutus Biopharma Corp's next catalyst?
Arbutus Biopharma Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy" — expected August 15, 2030.
Who is the CEO of Arbutus Biopharma Corp?
Ms. Lindsay Androski J.D., M.B.A. is the chief executive officer of Arbutus Biopharma Corp (ABUS).
Where is Arbutus Biopharma Corp headquartered?
Arbutus Biopharma Corp (ABUS) is headquartered in Warminster, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.